MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 4.3% – Here’s What Happened

Shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) traded down 4.3% on Thursday . The company traded as low as $1.09 and last traded at $1.10. 69,365 shares were traded during trading, a decline of 96% from the average session volume of 1,921,606 shares. The stock had previously closed at $1.15.

MIRA Pharmaceuticals Trading Down 3.6 %

The stock’s 50-day moving average is $1.12 and its two-hundred day moving average is $1.22. The company has a market capitalization of $17.55 million, a PE ratio of -1.89 and a beta of 2.31.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. On average, equities research analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Trading of MIRA Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRA. International Assets Investment Management LLC purchased a new stake in shares of MIRA Pharmaceuticals during the fourth quarter valued at $29,000. Two Sigma Investments LP acquired a new stake in shares of MIRA Pharmaceuticals during the fourth quarter worth about $28,000. Citadel Advisors LLC acquired a new position in MIRA Pharmaceuticals in the 4th quarter worth approximately $112,000. Northern Trust Corp boosted its holdings in shares of MIRA Pharmaceuticals by 50.9% in the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after acquiring an additional 10,238 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $52,000. 35.16% of the stock is currently owned by institutional investors.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.